On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Medtronic MDT. "I like what they’re doing in AI. You’ve got a good one with a good yield," he noted.
On March 27, the FDA approved Medtronic’s Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
Riley Exploration Permian, Inc. REPX is actually a very cheap stock, and it has got a good yield. "I don’t understand why it’s here, and I think you should buy it," he added.
On April 4, Riley Permian announced pricing of public offering of $18.9 million common stock at $27.00 per share.
The "Mad Money" host recommended buying WESCO International, Inc. WCC.
On April 1, Wesco International said it has completed the sale of its Wesco Integrated Supply business to Vallen Distribution, Inc for a purchase price of $350 million.
When asked about Cleveland-Cliffs Inc. CLF, he said, "I would buy that stock under 20, that’s my level."
On April 9, Wolfe Research downgraded Cleveland-Cliffs from Peer Perform to Underperform.
Price Action:
- Medtronic shares gained 1.1% to settle at $83.80 on Tuesday.
- Riley Exploration Permian shares fell 1.4% to close at $29.20 during Tuesday’s session.
- Shares of Wesco gained 0.1% to close at $172.78 on Tuesday.
- Cleveland-Cliffs shares fell 2.3% to settle at $21.91 on Tuesday.
Read Next: Citizens And 2 Other Stocks Under $3 Insiders Are Buying
Image: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
